BRPI0808293A2 - "composições para administração nasal" - Google Patents
"composições para administração nasal"Info
- Publication number
- BRPI0808293A2 BRPI0808293A2 BRPI0808293-6A BRPI0808293A BRPI0808293A2 BR PI0808293 A2 BRPI0808293 A2 BR PI0808293A2 BR PI0808293 A BRPI0808293 A BR PI0808293A BR PI0808293 A2 BRPI0808293 A2 BR PI0808293A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- nasal administration
- nasal
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90734007P | 2007-03-29 | 2007-03-29 | |
| US60/907,340 | 2007-03-29 | ||
| PCT/IL2008/000445 WO2008120207A2 (en) | 2007-03-29 | 2008-03-30 | Compositions for nasal delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0808293A2 true BRPI0808293A2 (pt) | 2019-09-24 |
Family
ID=39731229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0808293-6A BRPI0808293A2 (pt) | 2007-03-29 | 2008-03-30 | "composições para administração nasal" |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8911751B2 (pt) |
| EP (1) | EP2139449A2 (pt) |
| JP (1) | JP2010522741A (pt) |
| CN (2) | CN101720220A (pt) |
| AU (1) | AU2008234535A1 (pt) |
| BR (1) | BRPI0808293A2 (pt) |
| CA (1) | CA2683217A1 (pt) |
| EA (1) | EA200901319A1 (pt) |
| MX (1) | MX2009010289A (pt) |
| WO (1) | WO2008120207A2 (pt) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911751B2 (en) | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| JP5613657B2 (ja) | 2008-03-28 | 2014-10-29 | ヘイル バイオファーマ ベンチャーズ，エルエルシー | ベンゾジアゼピン組成物の投与 |
| WO2010080909A1 (en) | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| US20120171246A1 (en) | 2009-09-10 | 2012-07-05 | Yale University | Immunization to reduce neurotoxicity during treatment with cytolytic viruses |
| WO2011056993A1 (en) | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
| US20110212181A1 (en) * | 2010-02-26 | 2011-09-01 | The University Of Hong Kong | Compositions and methods for treating chronic respiratory inflammation |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| DK2706982T4 (da) | 2011-05-13 | 2021-05-10 | Euro Celtique Sa | Intranasale farmaceutiske dosisformer omfattende naloxon |
| DK3415139T3 (da) | 2011-06-14 | 2022-06-20 | Neurelis Inc | Administration af benzodiazepin |
| WO2014159878A2 (en) | 2013-03-13 | 2014-10-02 | Regents Of The University Of California | Intranasal administration of guanidinylated aminoglycosides |
| US20150086616A1 (en) * | 2013-09-20 | 2015-03-26 | Steven Lehrer | Method for the prevention and treatment of alzheimer's disease |
| WO2015077714A1 (en) | 2013-11-22 | 2015-05-28 | Yale University | Chimeric vsv virus compositions and methods of use thereof for treatment of cancer |
| US10493122B2 (en) | 2014-03-17 | 2019-12-03 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| US10052339B2 (en) * | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
| US10471040B2 (en) * | 2014-10-03 | 2019-11-12 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
| US20170326102A1 (en) * | 2014-11-27 | 2017-11-16 | Cipla Limited | Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery |
| DK3232808T3 (da) * | 2014-12-19 | 2020-06-02 | Thc Pharm Gmbh The Health Concept | CBD-holdig drik |
| WO2016161537A1 (en) * | 2015-04-08 | 2016-10-13 | Maxinase Life Sciences Limited | Bioadhesive compositions for intranasal administration of granistron |
| US20180126014A1 (en) | 2015-04-15 | 2018-05-10 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
| GB201508656D0 (en) | 2015-05-20 | 2015-07-01 | Sunstone Ip Systems Ltd | Portable power generating apparatus |
| GB2544468A (en) * | 2015-11-12 | 2017-05-24 | Jaytee Biosciences Ltd | Liquid formulation |
| WO2017093986A1 (en) * | 2015-12-05 | 2017-06-08 | Canabuzz-Med | Veterinary composition and methods for production and use |
| US9833408B1 (en) * | 2016-07-28 | 2017-12-05 | Allen Greenspoon | Orally administrable formulation |
| US10449230B2 (en) | 2016-10-06 | 2019-10-22 | The Regents Of The University Of California | Polymyxin derived cell penetrating scaffolds |
| JP2019537628A (ja) * | 2016-11-02 | 2019-12-26 | ティクン オラム リミテッドＴｉｋｕｎ Ｏｌａｍ ＬＴＤ | 併用療法 |
| JP2019533731A (ja) * | 2016-11-02 | 2019-11-21 | ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ | Ｃｂｄとコパキソンの併用療法 |
| KR101810160B1 (ko) | 2017-06-30 | 2018-01-25 | 주식회사 셀리제코스메틱 | 생리활성물질이 봉입된 에토좀 제조 방법, 에토좀 조성물 및 에토좀 조성물을 포함하는 화장료 조성물 |
| CN111278425B (zh) * | 2017-09-11 | 2024-06-11 | 耶路撒冷希伯来大学伊萨姆研究开发有限公司 | 用于向脑部经鼻给药药物和用于全身作用的组合物和方法 |
| US20200345656A1 (en) | 2017-11-29 | 2020-11-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoids compositions and methods |
| WO2020018705A1 (en) | 2018-07-17 | 2020-01-23 | Yale University | Methods for treatment of cancer using chikungunya-vsv chimeric virus |
| CA3119037A1 (en) | 2018-12-11 | 2020-06-18 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
| EP3941450A4 (en) * | 2019-03-22 | 2022-12-21 | Dbbh, Llc | INTRANASAL ANTIHISTAMINES AND ASSOCIATED USES |
| US20220211615A1 (en) * | 2019-04-30 | 2022-07-07 | Trigone Pharma Ltd. | Formulations and methods for drug instillation into the bladder and treatment of bladder ailments |
| CN114980896A (zh) * | 2019-08-07 | 2022-08-30 | 阿克里普斯一有限公司 | (6AS)-6-甲基-5,6,6A,7-四氢-4H-二苯并[de,g]喹啉-10,11-二醇的药物组合物 |
| CN110433133A (zh) * | 2019-08-19 | 2019-11-12 | 中国人民解放军军事科学院军事医学研究院 | 治疗创伤后应激障碍的大麻二酚鼻用制剂 |
| WO2021091905A1 (en) * | 2019-11-08 | 2021-05-14 | Vella Bioscience, Inc. | Liposomal formulations for delivery of cannabinoids and methods of making thereof |
| IL298432A (en) * | 2020-05-26 | 2023-01-01 | Strategic Drug Solutions Inc | Formulations and methods for treating erectile dysfunction |
| WO2021247447A1 (en) * | 2020-06-01 | 2021-12-09 | Luke Klele | Antiviral compositions |
| WO2022011460A1 (en) * | 2020-07-13 | 2022-01-20 | Hexo Operations Inc. | Transmucosal cannabis compositions with enhanced permeation properties |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| CA3173494A1 (en) * | 2020-09-24 | 2022-03-31 | Michael Foster DAVIS | Cannabinoid composition comprising at least 50% carrier |
| KR20230144019A (ko) * | 2021-01-08 | 2023-10-13 | 뉴렐리스 인코포레이티드 | 항발작 치료제의 신속한 전달을 위한 방법 및 조성물 |
| US12599611B2 (en) | 2021-06-10 | 2026-04-14 | Neurelis, Inc. | Methods and compositions for treating seizure disorders in pediatric patients |
| US20250025461A1 (en) * | 2021-07-23 | 2025-01-23 | Purdue Research Foudation | Treatment of severe and uncomplicated malaria |
| EP4415708A4 (en) * | 2021-10-13 | 2025-07-30 | Pneuma Respiratory Inc | COMPOSITIONS FOR THE ADMINISTRATION OF CANNABINOIDS |
| IT202200009092A1 (it) * | 2022-05-04 | 2023-11-04 | Emilia ARMENIA | Transetosomi per la veicolazione di farmaci |
| JP2025527938A (ja) | 2022-08-22 | 2025-08-25 | ユニバーシティ オブ タルトゥ | 脳透過性ペプチドおよびその使用方法 |
| CN120129696A (zh) | 2022-09-01 | 2025-06-10 | 乔治亚大学研究基金公司 | 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA821577B (en) * | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
| NL193099C (nl) * | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
| DE3650772T2 (de) | 1985-04-27 | 2003-04-03 | F. Hoffmann-La Roche Ag, Basel | Derivate von Indazole-3-carboxamide und -3-carboxylsäure |
| GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| US5741513A (en) * | 1990-02-08 | 1998-04-21 | A. Natterman & Cie. Gmbh | Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it |
| US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| US6350458B1 (en) * | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| GB9807639D0 (en) | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| PT1094781E (pt) | 1998-07-07 | 2008-10-08 | Transdermal Technologies Inc | Composições para administração transdérmica rápida e não irritante de agentes farmacologicamente activos e métodos para formulação de tais composições e sua administração |
| US20020048551A1 (en) * | 1999-04-06 | 2002-04-25 | Keller Brian C. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
| AU778896B2 (en) | 1999-07-26 | 2004-12-23 | Sk Biopharmaceuticals Co., Ltd. | Transnasal anticonvulsive compositions and modulated process |
| US20040204413A1 (en) * | 2001-01-26 | 2004-10-14 | Joaquina Faour | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant |
| NL1017421C2 (nl) * | 2001-02-21 | 2002-01-15 | Synthon Bv | Werkwijze voor het vervaardigen van paroxetine. |
| WO2003000174A2 (en) | 2001-06-26 | 2003-01-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for intracellular delivery |
| EP1465899A1 (en) | 2001-12-06 | 2004-10-13 | Ufc Limited | Trioxane derivatives |
| ES2197001B1 (es) | 2002-03-26 | 2004-11-16 | Laboratorios Vita, S.A. | Procedimiento de obtencion de un compuesto farmaceuticamente activo. |
| WO2003099293A1 (en) | 2002-05-23 | 2003-12-04 | Danmarks Farmaceutiske Universitet | Pharmacologically active salts |
| BRPI0416268A (pt) * | 2003-11-05 | 2007-12-11 | Unimed Pharmaceuticals Inc | composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla |
| WO2005107467A2 (en) | 2004-05-03 | 2005-11-17 | Descartes Therapeutics, Inc. | Compositions including opioids and methods of their use in treating pain |
| EP1768650B1 (en) | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| US20060229233A1 (en) | 2004-06-25 | 2006-10-12 | Id Biomedical Corporation | Compositions and methods for treating neurological disorders |
| US7855196B2 (en) * | 2005-08-22 | 2010-12-21 | Pierre Mainville | Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist |
| PT1933809E (pt) | 2005-10-11 | 2012-04-26 | Yissum Res Dev Co | Composições para administração por via nasal |
| US8911751B2 (en) | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| DE102006027793A1 (de) | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Opioid-Kombinations-Wafer |
| ATE440598T1 (de) | 2007-03-02 | 2009-09-15 | Flamek Corp Ou | Analgesische zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden arzneimitteln und opioiden |
-
2008
- 2008-03-28 US US12/078,317 patent/US8911751B2/en not_active Expired - Fee Related
- 2008-03-30 EA EA200901319A patent/EA200901319A1/ru unknown
- 2008-03-30 WO PCT/IL2008/000445 patent/WO2008120207A2/en not_active Ceased
- 2008-03-30 CN CN200880018261A patent/CN101720220A/zh active Pending
- 2008-03-30 CN CN2012101842578A patent/CN102743740A/zh active Pending
- 2008-03-30 BR BRPI0808293-6A patent/BRPI0808293A2/pt not_active IP Right Cessation
- 2008-03-30 JP JP2010500438A patent/JP2010522741A/ja active Pending
- 2008-03-30 AU AU2008234535A patent/AU2008234535A1/en not_active Abandoned
- 2008-03-30 CA CA002683217A patent/CA2683217A1/en not_active Abandoned
- 2008-03-30 MX MX2009010289A patent/MX2009010289A/es not_active Application Discontinuation
- 2008-03-30 EP EP08720063A patent/EP2139449A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010522741A (ja) | 2010-07-08 |
| MX2009010289A (es) | 2010-03-08 |
| CN102743740A (zh) | 2012-10-24 |
| CA2683217A1 (en) | 2008-10-09 |
| CN101720220A (zh) | 2010-06-02 |
| US8911751B2 (en) | 2014-12-16 |
| US20090047234A1 (en) | 2009-02-19 |
| WO2008120207A3 (en) | 2009-01-29 |
| AU2008234535A1 (en) | 2008-10-09 |
| EP2139449A2 (en) | 2010-01-06 |
| WO2008120207A2 (en) | 2008-10-09 |
| EA200901319A1 (ru) | 2010-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0810928A2 (pt) | "composição farmacêutica" | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| LTC2140867I2 (lt) | Farmacinė kompozicija | |
| EP3777939C0 (en) | NASAL ROYALTY | |
| BRPI0913379A2 (pt) | formulações farmacêuticas sólidas compreendendo bibw 2992 | |
| DK3492069T3 (da) | Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid | |
| DK1984009T3 (da) | Farmaceutiske sammensætninger med forbedret stabilitet | |
| BRPI0721651A2 (pt) | Composição farmacêutica | |
| PT2066179T (pt) | Formulações para administração tópica local contendo indoxacarb | |
| BRPI0815452A2 (pt) | "equipamento para gastropexia" | |
| BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| BRPI0715712A2 (pt) | Composição farmacêutica | |
| EP2280916A4 (en) | HYDROCHLORFLUOROLEFINZUSAMMENSETZUNGEN | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| DK2966175T3 (da) | Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat | |
| DK2120884T3 (da) | Farmaceutisk sammensætning | |
| HUE037800T2 (hu) | Gyógyszerkészítmény ektoparaziták leküzdésére | |
| BRPI0720234A2 (pt) | Composição farmacêutica | |
| BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
| BRPI0819566A2 (pt) | "composições antissépticas para tecidos" | |
| DK2018158T3 (da) | Ny racecadotril administrationsform | |
| EP2214625A4 (en) | EMULSION COMPOSITION | |
| PT2209464E (pt) | Composição farmacêutica antimalárica | |
| BRPI0820198A2 (pt) | composições farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |